Cargando…

Brentuximab vedotin: axonal microtubule's Apollyon

Detalles Bibliográficos
Autores principales:	Mariotto, S, Ferrari, S, Sorio, M, Benedetti, F, Tridente, G, Cavallaro, T, Gajofatto, A, Monaco, S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4558596/ https://www.ncbi.nlm.nih.gov/pubmed/26314985 http://dx.doi.org/10.1038/bcj.2015.72

Ejemplares similares

Brentuximab Vedotin
Publicado: (2012)

Cutaneous Anaplastic Large-Cell Lymphoma with Dramatic Response to Brentuximab Vedotin
por: Şahin, Mustafa, et al.
Publicado: (2021)

Safety and efficacy of brentuximab vedotin as a treatment for lymphoproliferative disorders in primary immunodeficiencies
por: Pincez, Thomas, et al.
Publicado: (2020)

Brentuximab vedotin induced uveitis
por: Therssen, Stijn, et al.
Publicado: (2022)

Complete remission in CD30-positive refractory extranodal NK/T-cell lymphoma with brentuximab vedotin
por: Kim, Hee Kyung, et al.
Publicado: (2015)

Safety of Concurrent Radiation Therapy With Brentuximab Vedotin in the Treatment of Lymphoma
por: Wu, Susan Y., et al.
Publicado: (2023)

Brentuximab Vedotin in CD30+ Lymphomas
por: Perini, Guilherme Fleury, et al.
Publicado: (2013)

Successful salvage therapy for refractory primary cutaneous gamma-delta T-cell lymphoma with a combination of brentuximab vedotin and gemcitabine
por: Voruz, Sophie, et al.
Publicado: (2021)

Vaginal ALK-positive anaplastic large cell lymphoma treated with brentuximab vedotin: a case report and literature review
por: Cortez, Anita Cassoli, et al.
Publicado: (2022)

Brentuximab vedotin for relapsed or refractory Hodgkin’s lymphoma
por: Chen, Runzhe, et al.
Publicado: (2015)

Brentuximab vedotin: clinical updates and practical guidance
por: Yi, Jun Ho, et al.
Publicado: (2017)

A phase II study of brentuximab vedotin in patients with relapsed or refractory Epstein-Barr virus-positive and CD30-positive lymphomas
por: Kim, Miso, et al.
Publicado: (2021)

Desensitization of Brentuximab Vedotin in a Patient with Hodgkin Lymphoma
por: Khalid, Sidra, et al.
Publicado: (2018)

Brentuximab Vedotin Treatment for Primary Refractory Hodgkin Lymphoma
por: Wu, Hung-Bo, et al.
Publicado: (2013)

Brentuximab vedotin: targeting CD30 as standard in CTCL
por: Prince, H. Miles, et al.
Publicado: (2018)

The Evolving Role of Brentuximab Vedotin in Classical Hodgkin Lymphoma
por: Lai, Catherine, et al.
Publicado: (2019)

Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey
por: Salihoglu, A., et al.
Publicado: (2014)

Brentuximab Vedotin Plus CHP in Frontline sALCL: Adjusted Estimates of Efficacy and Cost-Effectiveness Removing the Effects of Re-Treatment with Brentuximab Vedotin
por: Cranmer, Holly, et al.
Publicado: (2022)

Brentuximab vedotin in the treatment of elderly Hodgkin lymphoma patients at first relapse or with primary refractory disease: a phase II study of FIL ONLUS
por: Stefoni, Vittorio, et al.
Publicado: (2020)

Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. The Hellenic experience
por: Angelopoulou, Maria K., et al.
Publicado: (2017)

Brentuximab Vedotin in Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma
por: Tsang, Vivian
Publicado: (2012)

Role of brentuximab vedotin in the treatment of relapsed or refractory Hodgkin lymphoma
por: Siddiqi, Tanya, et al.
Publicado: (2014)

Brentuximab Vedotin Infusion Reaction Management: A Case Study
por: Comer, Holly, et al.
Publicado: (2017)

Safety and Efficacy of Brentuximab Vedotin in the Treatment of Classic Hodgkin Lymphoma
por: Makita, Shinichi, et al.
Publicado: (2020)

Brentuximab vedotin-associated diabetic ketoacidosis: a case report
por: Köksalan, Damla, et al.
Publicado: (2022)

Diabetic Ketoacidosis and Profound Insulin Resistance From Brentuximab Vedotin
por: Thakkar, Keval, et al.
Publicado: (2023)

Brentuximab vedotin use in pediatric anaplastic large cell lymphoma
por: Agrusa, Jennifer E., et al.
Publicado: (2023)

Outcomes of refractory or relapsed Hodgkin lymphoma patients with post-autologous stem cell transplantation brentuximab vedotin maintenance: a French multicenter observational cohort study
por: Marouf, Amira, et al.
Publicado: (2021)

The Successful Use of Neo Adjuvant Brentuximab Vedotin in the Treatment of BIA-ALCL
por: Allchin, Rebecca L., et al.
Publicado: (2020)

Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies
por: Bartlett, Nancy L, et al.
Publicado: (2014)

Emerging Pharmacotherapy for Relapsed or Refractory Hodgkin’s Lymphoma: Focus on Brentuximab Vedotin
por: Furtado, Michelle, et al.
Publicado: (2012)

Improvement of Cutaneous Anaplastic Large Cell Lymphoma by Brentuximab Vedotin Monotherapy
por: Onaka, Takashi, et al.
Publicado: (2018)

Rapid desensitization for brentuximab vedotin (Adceteris(®)) allergy: a case report
por: Di Girolamo, Attilio, et al.
Publicado: (2018)

Brentuximab Vedotin: A Review in CD30-Positive Hodgkin Lymphoma
por: Scott, Lesley J.
Publicado: (2017)

Hodgkin Lymphoma on Hemodialysis Successfully Treated with Extended Courses of Brentuximab Vedotin
por: Uchimura, Ayana, et al.
Publicado: (2022)

Response to Brentuximab Vedotin by CD30 Expression in Non-Hodgkin Lymphoma
por: Jagadeesh, Deepa, et al.
Publicado: (2022)

Immediate Response to Brentuximab Vedotin in a Patient with Localized MF-LCT
por: Giza, Agnieszka, et al.
Publicado: (2023)

Combination brentuximab vedotin and bendamustine for pediatric patients with relapsed/refractory Hodgkin lymphoma
por: Forlenza, Christopher J., et al.
Publicado: (2021)

Frontline brentuximab vedotin in breast implant‐associated anaplastic large‐cell lymphoma
por: Alderuccio, Juan Pablo, et al.
Publicado: (2018)

A Chinese patient with relapsed and refractory Hodgkin lymphoma treated with brentuximab vedotin
por: Cao, Zhi-Gang, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_6f0io9bod9dbj5btejadj8jpmn